Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
American Realty Investors
ARL
$243M
| $567K | ﹤0.01% |
33,100
-3,900
| -11% | -$58.1K |
|
2852
ImmuCell
ICCC
$99.3M
| $567K | ﹤0.01% |
110,106
+14,000
| +15% | +$72.2K |
|
2853
iShares Biotechnology ETF
IBB
$9.77B
| $566K | ﹤0.01% |
+4,700
| New | +$524K |
|
2854
Yatra Online
YTRA
$56M
| $564K | ﹤0.01% |
179,200
+1,100
| +0.6% | +$4.06K |
|
2855
Covenant Logistics
CVLG
$865M
| $563K | ﹤0.01% |
87,126
-15,274
| -15% | -$111K |
|
2856
KKR & Co
KKR
$103B
| $562K | ﹤0.01% |
+19,250
| New | +$548K |
|
2857
J. Jill
JILL
$279M
| $561K | ﹤0.01% |
99,323
+41,703
| +72% | +$327K |
|
2858
Kodak
KODK
$978M
| $555K | ﹤0.01% |
+119,300
| New | +$330K |
|
|
IRS
2859
IRSA Inversiones y Representaciones
IRS
$1.24B
| $554K | ﹤0.01% |
77,647
+1,240
| +2% | +$7.12K |
|
|
TULP
2860
Bloomia Holdings
TULP
$17.2M
| $554K | ﹤0.01% |
108,498
+557
| +0.5% | +$3.58K |
|
2861
La-Z-Boy
LZB
$1.64B
| $554K | ﹤0.01% |
17,600
-252,800
| -93% | -$8.48M |
|
|
NEW
2862
DELISTED
Puxin Limited American Depositary Shares, each representing twenty Ordinary Shares
NEW
| $554K | ﹤0.01% |
6,758
+4,271
| +172% | +$389K |
|
|
ACRE
2863
Ares Commercial Real Estate
ACRE
$264M
| $552K | ﹤0.01% |
34,828
-61,372
| -64% | -$951K |
|
2864
Daily Journal
DJCO
$828M
| $552K | ﹤0.01% |
1,900
+100
| +6% | +$28K |
|
|
LL
2865
DELISTED
LL Flooring Holdings, Inc.
LL
| $552K | ﹤0.01% |
56,500
+40,300
| +249% | +$377K |
|
2866
WisdomTree US LargeCap Dividend Fund
DLN
$6.45B
| $551K | ﹤0.01% |
10,400
+5,600
| +117% | +$285K |
|
2867
Pembina Pipeline
PBA
$28.4B
| $551K | ﹤0.01% |
14,864
-258,300
| -95% | -$9.24M |
|
2868
State Street SPDR Dow Jones Global Real Estate ETF
RWO
$1.29B
| $551K | ﹤0.01% |
10,700
+700
| +7% | +$36.4K |
|
|
FLXN
2869
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $551K | ﹤0.01% |
26,600
-15,800
| -37% | -$266K |
|
|
STKL
2870
DELISTED
SunOpta
STKL
| $546K | ﹤0.01% |
218,500
-189,148
| -46% | -$421K |
|
2871
BlackBerry
BB
$5.27B
| $544K | ﹤0.01% |
84,700
-3,605,644
| -98% | -$19.8M |
|
|
STRM
2872
DELISTED
Streamline Health Solutions
STRM
| $544K | ﹤0.01% |
26,085
+1,975
| +8% | +$36.4K |
|
|
ATXS
2873
DELISTED
Astria Therapeutics
ATXS
| $542K | ﹤0.01% |
15,274
+9,240
| +153% | +$291K |
|
2874
Andersons Inc
ANDE
$2.21B
| $541K | ﹤0.01% |
21,400
-412,976
| -95% | -$9.02M |
|
|
MBAI
2875
Check-Cap
MBAI
$9.75M
| $541K | ﹤0.01% |
2,245
-9
| -0.4% | -$2.09K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.